Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.82 USD | +0.48% | +6.33% | +18.56% |
05-07 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
05-07 | Transcript : Halozyme Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.56% | 5.55B | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics Insider Sold Shares Worth $788,670, According to a Recent SEC Filing